LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID

The present invention relates to compositions for in vitro and in vivo delivery of nucleic acids, in particular messenger RNAs (mRNAs), into a target cell and their applications. The present invention is directed to a composition comprising (A) at least one nucleic acid and (B) at least one lipid na...

Full description

Saved in:
Bibliographic Details
Main Authors HELLAL, Malik, GUEGUEN, Claire
Format Patent
LanguageEnglish
French
Published 11.01.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to compositions for in vitro and in vivo delivery of nucleic acids, in particular messenger RNAs (mRNAs), into a target cell and their applications. The present invention is directed to a composition comprising (A) at least one nucleic acid and (B) at least one lipid nanoparticle (LNP) comprising (i) at least one ionizable lipid; (ii) at least one phospholipid; (iii) at least one sterol, especially neutral sterol; (iv) at least one poly(ethyleneglycol)-lipid (PEG-lipid); and (v) an imidazolium-based cationic lipid of formula (I), wherein R1 R2, R3, R4, R5, R6, R7, R8 and R9, Y and A- are as defined in the description. The present invention also relates to a method for in vitro or in vivo transfection of live cells and uses of said composition. La présente invention concerne des compositions pour administration in vitro et in vivo d'acides nucléiques, en particulier des ARN messagers (ARNm), dans une cellule cible et leurs applications. La présente invention concerne une composition comprenant (A) au moins un acide nucléique et (B) au moins une nanoparticule lipidique (NPL) comprenant (i) au moins un lipide ionisable ; (ii) au moins un phospholipide ; (iii) au moins un stérol, en particulier un stérol neutre ; (iv) au moins un poly(éthylèneglycol)-lipide (PEG-lipide) ; et (v) un lipide cationique à base d'imidazolium de formule (I), dans laquelle R1 R2, R3, R4, R5, R6, R7, R8 et R9, Y et A- sont tels que définis dans la description. La présente invention concerne également un procédé de transfection in vitro ou in vivo de cellules vivantes et des utilisations de ladite composition.
Bibliography:Application Number: WO2023EP68940